KALA BIO, Inc. Files 8-K on Exit Activities
Ticker: KALA · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1479419
| Field | Detail |
|---|---|
| Company | Kala Bio, INC. (KALA) |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: restructuring, disposal, corporate-actions
TL;DR
KALA BIO filing 8-K for exit/disposal costs - potential restructuring ahead.
AI Summary
KALA BIO, Inc. filed an 8-K on September 29, 2025, reporting on events as of September 28, 2025. The filing indicates costs associated with exit or disposal activities, other events, and financial statements and exhibits. The company, formerly known as Kala Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in Arlington, MA.
Why It Matters
This 8-K filing signals potential restructuring or discontinuation of certain operations by KALA BIO, Inc., which could impact its future business strategy and financial performance.
Risk Assessment
Risk Level: medium — Filings related to exit or disposal activities often indicate significant business changes or financial challenges that could pose risks to investors.
Key Players & Entities
- KALA BIO, Inc. (company) — Registrant
- Kala Pharmaceuticals, Inc. (company) — Former company name
- September 28, 2025 (date) — Earliest event date
- September 29, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- Arlington, MA (location) — Principal Executive Offices
FAQ
What specific activities are associated with the exit or disposal mentioned in the filing?
The filing indicates 'Cost Associated with Exit or Disposal Activities' as an item, but the specific details of these activities are not elaborated in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on September 28, 2025.
What is the principal executive office address for KALA BIO, Inc.?
The principal executive office address for KALA BIO, Inc. is 1167 Massachusetts Avenue, Arlington, MA 02476.
What was KALA BIO, Inc. formerly known as?
KALA BIO, Inc. was formerly known as Kala Pharmaceuticals, Inc.
What is the fiscal year end for KALA BIO, Inc.?
The fiscal year end for KALA BIO, Inc. is December 31.
Filing Stats: 1,051 words · 4 min read · ~4 pages · Grade level 12.9 · Accepted 2025-09-29 08:08:47
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share KALA The Nasdaq C
Filing Documents
- tm2527340d1_8k.htm (8-K) — 28KB
- tm2527340d1_ex99-1.htm (EX-99.1) — 10KB
- tm2527340d1_ex99-1img01.jpg (GRAPHIC) — 4KB
- 0001104659-25-094125.txt ( ) — 208KB
- kala-20250928.xsd (EX-101.SCH) — 3KB
- kala-20250928_lab.xml (EX-101.LAB) — 33KB
- kala-20250928_pre.xml (EX-101.PRE) — 22KB
- tm2527340d1_8k_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release of KALA BIO, Inc. dated September 29, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: September 29, 2025 By: /s/ Mary Reumuth Mary Reumuth Chief Financial Officer and Corporate Secretary